This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GILD vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. TECH: Which Stock Is the Better Value Option?
Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down
by Zacks Equity Research
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
Gilead (GILD) Partners With Eisai for RA Candidate in Japan
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $66.72, moving -0.04% from the previous trading session.
GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA
by Zacks Equity Research
GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
by Zacks Equity Research
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Gilead (GILD) Announces Top-Line Results From NASH Study
by Zacks Equity Research
Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $66.12 in the latest trading session, marking a +0.53% move from the prior day.
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
by Zacks Equity Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
by Zacks Equity Research
The biotech sector witnesses pipeline updates from the annual ASH meet.
The Zacks Analyst Blog Highlights: Toyota, CVS, 3M, Gilead and Goldman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Toyota, CVS, 3M, Gilead and Goldman
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $67.08, moving +0.22% from the previous trading session.
Fate (FATE) Announces Encouraging Data on Immunotherapies
by Zacks Equity Research
Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.
Top Stock Reports for Toyota, CVS Health & 3M
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), CVS Health (CVS) and 3M (MMM).
Gilead (GILD) Announces Positive Long-Term Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space
by Zacks Equity Research
Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.
Intercept's (ICPT) NDA for NASH Drug Gets Priority Review
by Zacks Equity Research
Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.
AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL
by Zacks Equity Research
The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.
Biotech ETF (BBH) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv